$AWH
Aspira Women's Health Inc.

2021 Q1 Form 10-Q Financial Statement

#000092661721000057 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $1.496M $1.220M
YoY Change 22.62% 51.93%
Cost Of Revenue $893.0K $800.0K
YoY Change 11.63% 15.27%
Gross Profit $603.0K $420.0K
YoY Change 43.57% 285.32%
Gross Profit Margin 40.31% 34.43%
Selling, General & Admin $5.617M $3.825M
YoY Change 46.85% 5.69%
% of Gross Profit 931.51% 910.71%
Research & Development $872.0K $395.0K
YoY Change 120.76% 89.0%
% of Gross Profit 144.61% 94.05%
Depreciation & Amortization $90.00K $56.00K
YoY Change 60.71% -54.84%
% of Gross Profit 14.93% 13.33%
Operating Expenses $6.489M $4.220M
YoY Change 53.77% 10.24%
Operating Profit -$5.886M -$3.800M
YoY Change 54.89% 2.18%
Interest Expense -$20.00K $10.00K
YoY Change -300.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$10.00K $86.00K
YoY Change -111.63% -2250.0%
Pretax Income -$5.920M -$3.710M
YoY Change 59.57% -0.27%
Income Tax
% Of Pretax Income
Net Earnings -$5.920M -$3.706M
YoY Change 59.74% -0.27%
Net Earnings / Revenue -395.72% -303.77%
Basic Earnings Per Share
Diluted Earnings Per Share -$54.48K -$38.13K
COMMON SHARES
Basic Shares Outstanding 111.7M 97.29M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.40M $8.100M
YoY Change 633.33% 30.65%
Cash & Equivalents $59.37M $8.132M
Short-Term Investments
Other Short-Term Assets $1.000M $800.0K
YoY Change 25.0% 33.33%
Inventory $71.00K $63.00K
Prepaid Expenses
Receivables $952.0K $946.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $61.37M $9.986M
YoY Change 514.59% 31.81%
LONG-TERM ASSETS
Property, Plant & Equipment $533.0K $318.0K
YoY Change 67.61% -40.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $49.00K
YoY Change -100.0% -66.67%
Total Long-Term Assets $924.0K $367.0K
YoY Change 151.77% -45.87%
TOTAL ASSETS
Total Short-Term Assets $61.37M $9.986M
Total Long-Term Assets $924.0K $367.0K
Total Assets $62.30M $10.35M
YoY Change 501.73% 25.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.587M $1.595M
YoY Change -0.5% 37.86%
Accrued Expenses $3.471M $2.164M
YoY Change 60.4% 15.17%
Deferred Revenue
YoY Change
Short-Term Debt $400.0K $194.0K
YoY Change 106.19% 2.11%
Long-Term Debt Due $201.0K
YoY Change
Total Short-Term Liabilities $6.100M $3.985M
YoY Change 53.07% 19.45%
LONG-TERM LIABILITIES
Long-Term Debt $2.718M $1.050M
YoY Change 158.86% -15.59%
Other Long-Term Liabilities $400.0K $16.00K
YoY Change 2400.0% -56.76%
Total Long-Term Liabilities $2.718M $1.066M
YoY Change 154.97% -16.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.100M $3.985M
Total Long-Term Liabilities $2.718M $1.066M
Total Liabilities $10.00M $5.051M
YoY Change 97.98% 9.4%
SHAREHOLDERS EQUITY
Retained Earnings -$446.0M -$425.9M
YoY Change 4.72% 3.71%
Common Stock $112.0K $97.00K
YoY Change 15.46% 29.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $52.33M $5.302M
YoY Change
Total Liabilities & Shareholders Equity $62.30M $10.35M
YoY Change 501.73% 25.43%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$5.920M -$3.706M
YoY Change 59.74% -0.27%
Depreciation, Depletion And Amortization $90.00K $56.00K
YoY Change 60.71% -54.84%
Cash From Operating Activities -$5.255M -$3.501M
YoY Change 50.1% 12.64%
INVESTING ACTIVITIES
Capital Expenditures $41.00K $23.00K
YoY Change 78.26% -53.06%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$41.00K -$23.00K
YoY Change 78.26% -52.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $48.24M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 48.03M -47.00K
YoY Change -102300.0% 56.67%
NET CHANGE
Cash From Operating Activities -5.255M -3.501M
Cash From Investing Activities -41.00K -23.00K
Cash From Financing Activities 48.03M -47.00K
Net Change In Cash 42.74M -3.571M
YoY Change -1296.81% 12.08%
FREE CASH FLOW
Cash From Operating Activities -$5.255M -$3.501M
Capital Expenditures $41.00K $23.00K
Free Cash Flow -$5.296M -$3.524M
YoY Change 50.28% 11.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 awh Minimum Percentage Reduction Of False Elevations By Ova1plus
MinimumPercentageReductionOfFalseElevationsByOva1plus
0.40
CY2020Q1 awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
1000
CY2021Q1 awh Net Increase In Right Of Use Assets
NetIncreaseInRightOfUseAssets
-15000
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei City Area Code
CityAreaCode
512
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12117 Bee Caves Road
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building Three
CY2021Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 100
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78738
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000926617
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
111946449
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-34810
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Aspira Women's Health Inc.
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0595156
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
519-0400
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Trading Symbol
TradingSymbol
AWH
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1103000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1587000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
865000
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
952000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3618000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3471000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
449680000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
498199000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12543364
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10514070
CY2020Q4 us-gaap Assets
Assets
19605000
CY2021Q1 us-gaap Assets
Assets
62297000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18603000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
61373000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11703000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16631000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3571000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42738000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
104619876
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111716852
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111716852
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
105000
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
112000
CY2021Q1 us-gaap Contractual Obligation
ContractualObligation
3084000
CY2021Q1 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
1410000
CY2021Q1 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
461000
CY2021Q1 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
204000
CY2021Q1 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
406000
CY2021Q1 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
452000
CY2021Q1 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
151000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
800000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
893000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
56000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
29000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1710000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2509000
CY2020Q1 us-gaap Gross Profit
GrossProfit
420000
CY2021Q1 us-gaap Gross Profit
GrossProfit
603000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
291000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
111000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
87000
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
38000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
41000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
94000
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-24000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
9000
CY2020Q4 us-gaap Inventory Net
InventoryNet
30000
CY2021Q1 us-gaap Inventory Net
InventoryNet
71000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
558000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
95000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
64000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
123000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
116000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
106000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
54000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
125000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19605000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62297000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
4122000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
981000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
4073000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
645000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
645000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3477000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3428000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-47000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48034000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3501000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5255000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3706000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5920000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
4220000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
6489000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3800000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5886000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
433000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
37000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
409000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
396000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
406000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
391000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
16000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0936
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y2M12D
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
86000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2021Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
516000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1077000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48236000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
317000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
583000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
533000
CY2020Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
48000
CY2021Q1 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
3000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
395000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
872000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-440066000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-445986000
CY2020Q1 us-gaap Revenues
Revenues
1220000
CY2021Q1 us-gaap Revenues
Revenues
1496000
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2115000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3108000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
269000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
489000
CY2020Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
269000
CY2021Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
489000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
8738000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
5302000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9719000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
52325000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47720000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
317000
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
97287461
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108661712

Files In Submission

Name View Source Status
0000926617-21-000057-index-headers.html Edgar Link pending
0000926617-21-000057-index.html Edgar Link pending
0000926617-21-000057.txt Edgar Link pending
0000926617-21-000057-xbrl.zip Edgar Link pending
awh-20210331.xml Edgar Link completed
awh-20210331.xsd Edgar Link pending
awh-20210331x10q.htm Edgar Link pending
awh-20210331xex10_1.htm Edgar Link pending
awh-20210331xex31_1.htm Edgar Link pending
awh-20210331xex31_2.htm Edgar Link pending
awh-20210331xex32_1.htm Edgar Link pending
awh-20210331_cal.xml Edgar Link unprocessable
awh-20210331_def.xml Edgar Link unprocessable
awh-20210331_lab.xml Edgar Link unprocessable
awh-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending